Result of AGM

RNS Number : 9242E
Oxford Biomedica PLC
07 June 2012
 



FOR IMMEDIATE RELEASE

 

                                               

OXFORD BIOMEDICA PLC

ANNUAL GENERAL MEETING

 

Oxford, UK - 7 June 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

 

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

 

·      Resolution 7: to empower the Directors to allot equity securities, pursuant to section 551 of the Companies Act 2006 (the "Act"), up to an aggregate nominal amount of £3,149,585 with a further aggregate nominal amount of £3,149,585 authorised in connection with a rights issue, or where applicable, other proportionate offer;

 

·      Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares;

 

·      Resolution 9: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days' notice.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk.

 

Certified copies of the document setting out the above resolutions passed at the 2012 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

 

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (05 June 2012) there were 944,875,557 1p ordinary shares in issue, each carrying one vote per share.

 

 

 

Resolution

 

Votes 

For

Votes at 

Chairman's

Discretion

Votes at 

other proxy

Discretion

 

 Votes

Against

 

Votes 

Withheld

 

Total

votes cast

Result









Ordinary resolutions






1

334,190,163

765,212

447,598

878,280

802,841

337,084,094

Passed









2

291,370,322

757,259

447,598

35,830,273

8,678,642

337,084,094

Passed









3

331,941,913

756,295

447,598

2,983,405

954,883

337,084,094

Passed









4

334,468,411

756,295

447,598

446,405

965,385

337,084,094

Passed









5

333,401,900

756,295

447,598

478,823

1,999,478

337,084,094

Passed









6

335,032,894

627,980

447,598

143,561

832,061

337,084,094

Passed









330,398,126

659,364

447,598

2,869,269

2,709,737

337,084,094

Passed

Special resolutions






8

334,634,982

652,946

447,598

362,936

985,632

337,084,094

Passed









9

329,424,402

636,549

447,598

5,769,015

806,530

337,084,094

Passed









 

 

 

With regard to Resolution 7, this was taken on a poll called by the Chairman of the Company at the meeting and the results were as follows:

 

 

 

 

Votes 

For

 

 Votes

Against

 

Votes 

Withheld

 

Total

votes cast

Result






333,155,858

5,793,459

2,787,570

338,949,317

Passed






 

The number of votes validly cast in relation to Resolution 7 was 338,949,317 which constitutes 35.87% of the of the issued share capital of the Company.

-Ends-

 

For further information, please contact:

 

Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary Clark/Sarah Macleod/Claire Dickinson

M:Communications

 

Tel: +44 (0)20 7920 2360

 

 

Notes to editors

 

1. Oxford BioMedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.  The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb.  Further information is available at www.oxfordbiomedica.co.uk.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RAGSSWFDWFESEIM